Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New CRISPR-SKIP Technique Can More Specifically Target Genes

By Kenny Walter | August 17, 2018

Using new gene-editing tools, researchers have developed a way to both eliminate a mutated gene sequence and influence how the gene is expressed and regulated.

A team of researchers from the University of Illinois at Urbana-Champaign has adapted a new CRISPR technique to cause a cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building.

By targeting specific genes, researchers believe they could treat genetic diseases caused by mutations in the genome like Duchenne’s muscular dystrophy, Huntington’s disease and some forms of cancer.

CRISPR technologies usually turn genes off by breaking their DNA at the start of a targeted gene to induce mutations when the DNA binds back together. However, this can often cause DNA to break in places outside of the intended target that reattaches to different chromosomes.

The new technique—dubbed CRISPR-SKIP—alters a single point in the targeted DNA sequence rather than breaking entire DNA strands.

“Given the problems with traditional gene editing by breaking the DNA, we have to find ways of optimizing tools to accomplish gene modification,” Illinois bioengineering professor Pablo Perez-Pinera said in a statement. “This is a good one because we can regulate a gene without breaking genomic DNA.”

In mammal cells, genes are broken up into segments called exons that are interspersed with regions of DNA that do not appear to code for anything. After the cell’s machinery transcribes a gene into RNA to be translated into a protein, there are signals in the DNA sequence that indicates which portions are exons and which are not part of the gene.

The cell splices together the RNA transcribed from the coding portions to get one continuous RNA template that is used to make proteins.

The new CRISPR system alters just a single base before the beginning of an exon to cause the cell to read it as a non-coding portion.

“When the cell treats the exon as non-coding DNA, that exon is not included in mature RNA, effectively removing the corresponding amino acids from the protein,” Michael Gapinske, a bioengineering graduate student and first author of the paper, said in a statement.

The researchers found that by skipping exons in proteins that are missing a few amino acids, the truncated proteins would retain partial or full activity—which could be enough to restore function in some genetic diseases.

Other approaches to skip exons or eliminate amino acids only provide a temporary benefit because they do not permanently alter DNA and often require repeated administrations over the lifetime of the patient.

“By editing a single base in genomic DNA using CRISPR-SKIP, we can eliminate exons permanently and, therefore, achieve a long-lasting correction of the disease with a single treatment,” Alan Luu, a physics graduate student and co-first author of the study, said in a statement. “The process is also reversible if we would need to turn an exon back on.”

The researchers tested their new method in multiple cell lines of healthy and cancerous mice and humans.

“We tested it in three different mammalian cell lines to demonstrate that it can be applied to different types of cells,” Illinois physics professor Jun Song said in a statement. “We also demonstrated it in cancer cell lines because we wanted to show that we could target oncogenes. We haven’t used it in vivo; that will be the next step.”

They found that CRISPR-SKIP could target specific bases, skip exons with high efficiency and skip multiple exons in one gene if necessary.

“In Duchenne’s muscular dystrophy, for example, just correcting 5 to 10 percent of the cells is enough to achieve a therapeutic benefit,” Perez-Pinera said. “With CRISPR-SKIP, we have seen modification rates of more than 20 to 30 percent in many of the cell lines we have studied.”

The study was published in Genome Biology.  


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE